Importantly, the value of serum MIC-1 as a prognostic marker in CRC was evaluated, and its ability for tumor recurrence prediction was investigated; and to our knowledge, the present research is the first investigation into the potential clinical value of serum MIC-1 in CRC patients with liver metastasis at diagnosis and post-operation relapse. This evidence concerns the gene GDF15 and colorectal carcinoma.